India

Government Approval and Price Hikes for Essential Cancer Chemotherapy Drugs

Wednesday, June 10, 2026
5 min read
Government Approval and Price Hikes for Essential Cancer Chemotherapy Drugs

The whole thing started with that shortage, you know? The first line cancer chemo drugs. News18 picked up on it last week the lack of access across India was already causing real treatment headaches.

Then there’s the mechanism behind trying to fix it. It all comes down to some legal maneuver.

They got this approval, sort of bending rules a bit, using para 19 of the DPCO, 2013. The Department of Pharmaceuticals wrote something to the NPPA about June 7th. They were asking for permission for these specific formulations.

It’s an exceptional power, that Para 19. It lets the government step in when they think prices or availability are breaking down. It bypasses the usual price control stuff.

The NPPA is supposed to be the watch dog there. It works under the Chemicals and Fertilizers Ministry, obviously.

But what happened next was a real back-and-forth between departments. The NPPA wrote to the economic adviser about four June. They were fielding requests from pharmaceutical companies wanting price hikes on certain scheduled drugs.

These companies cited everything: soaring API costs, production expenses jumping around, foreign exchange messing things up... all that kind of mess making manufacturing and marketing unsustainable.

So, the Inter-Ministerial Committee looked at it. Eighty-two formulations were involved in these requests. But only four really made the cut as urgent cases. Cisplatin and carboplatin the chemotherapy agents were right there on the list.

The committee’s reasoning was pretty stark. They saw what Tata Memorial Cancer Hospital was saying, that there were serious shortages of those injections. Carboplatin and Cisplatin injection. Critical stuff for first-line treatment.

It basically said: ensuring these medicines are available is a public health thing. That the immediate availability wasn't just an economic calculation.

For the other seventy-eight formulations? They needed more data. More information to properly examine them.

This led back to the permission hunt. NPPA had to ask the Department of Pharmaceuticals for that approval on raising prices. The DoP reviewed it, and they pushed back a little. There was a review meeting where the Secretary made it clear: any specific situation needing Para 19 invocation had to be flagged straight to the department first.

So finally, on June 7th, the DoP basically gave the Green light in principle. The minister’s approval for using those powers under Para 19 was there.

The instruction came down then: figure out how much they could raise prices. They suggested a formula ten percent yearly increase from the last fixed price, with a ceiling of fifty percent maybe, but cost increase should be the main driver.

Then the Department of Pharmaceuticals pushed back again to NPPA. They told the watchdog to look closely at the raw material costs for these drugs. Aligning any price hike with the actual effect on the price was crucial. And they asked NPPA to check if other companies were also asking for increases due to similar cost hikes on related materials.

It’s all tangled up, really. This government approval connects directly to that shortage crisis reported last week.

The reality on the ground? Oncologists are seeing the fallout daily. They told News18 about treatment delays. Dose reductions. Interrupted schedules. Inventory pressure is just routine now for these drugs. And this isn't just a supply issue anymore, it’s an economics problem. The companies made a business call: stop making what costs them money.

Now, with that government sign-off for potentially higher prices floating around, manufacturers suddenly have some breathing room to scale production back up. It changes the dynamic entirely.

Written by Gree News Team — Senior Editorial Board

Gree News Team covers international news and global affairs at Gree News. Our collective of senior editors is dedicated to providing independent, accurate, and responsible journalism for a global audience.

#sensational#india#global#trending

More from India

View All

Latest Headlines